Laboratorios RichmondC.I.F (BASE:RICHD) - Stock Price, News & Analysis

RICHD Stock Overview

A pharmaceutical company, develops and manufactures pharmaceutical products. More details

RICHD fundamental analysis
Snowflake Score
Valuation	2/6
Future Growth	0/6
Past Performance	2/6
Financial Health	2/6
Dividends	0/6

Rewards

Price-To-Earnings ratio (8.7x) is below the AR market (18.9x)

Became profitable this year

Risk Analysis

Debt is not well covered by operating cash flow

Shares are highly illiquid

Large one-off items impacting financial results

Laboratorios Richmond S.A.C.I.F. Competitors

Instituto Rosenbusch

BASE:ROSE

AR$4.7b

JW Holdings

KOSE:A096760

₩212.2b

Lincoln Pharmaceuticals

BSE:531633

₹12.6b

Kotra Industries Berhad

KLSE:KOTRA

RM 639.2m

Price History & Performance

Summary of all time highs, changes and price drops for Laboratorios RichmondC.I.F
Historical stock prices
Current Share Price	AR$0.75
52 Week High	AR$0.75
52 Week Low	AR$0.75
Beta	-0.067
11 Month Change	0%
3 Month Change	n/a
1 Year Change	n/a
33 Year Change	n/a
5 Year Change	n/a
Change since IPO	0%

Recent updates

Shareholder Returns

	RICHD	AR Pharmaceuticals	AR Market
7D	0%	-2.1%	6.6%
1Y	n/a	-17.9%	163.4%

Return vs Industry: Insufficient data to determine how RICHD performed against the AR Pharmaceuticals industry.

Return vs Market: Insufficient data to determine how RICHD performed against the AR Market.

Price Volatility

Is RICHD's price volatile compared to industry and market?
RICHD volatility
RICHD Average Weekly Movement	n/a
Pharmaceuticals Industry Average Movement	6.7%
Market Average Movement	5.7%
10% most volatile stocks in AR Market	7.2%
10% least volatile stocks in AR Market	4.3%

Stable Share Price: RICHD's share price has been volatile over the past 3 months compared to the AR market.

Volatility Over Time: Insufficient data to determine RICHD's volatility change over the past year.

About the Company

Founded	Employees	CEO	Website
1935	620	Juan Manuel Artola	www.richmondlab.com

Laboratorios Richmond S.A.C.I.F., a pharmaceutical company, develops and manufactures pharmaceutical products. It provides antiretroviral products for the treatment of human immunodeficiency virus (HIV); oncology and oncohematology drugs; cardiometabolic drugs, including antihypertensive, hypocholesterolemic, platelet antiaggregants, and hypoglycemic drugs; and neurological and psychiatric drugs comprising analgesic, antipsychotic, antidepressants, anti-dementia, antiepileptics, and hypnotic drugs, as well as drugs for the treatment of multiple sclerosis. The company sells its products in Latin America, Africa, Asia, and the Middle East.

Laboratorios Richmond S.A.C.I.F. Fundamentals Summary

How do Laboratorios RichmondC.I.F's earnings and revenue compare to its market cap?
RICHD fundamental statistics
Market cap	US$148.43m
Earnings (TTM)	US$17.06m
Revenue (TTM)	US$37.30m

8.7x

P/E Ratio

4.0x

P/S Ratio

Is RICHD overvalued?

See Fair Value and valuation analysis

Earnings & Revenue

Key profitability statistics from the latest earnings report (TTM)
RICHD income statement (TTM)
Revenue	AR$37.55b
Cost of Revenue	AR$11.93b
Gross Profit	AR$25.62b
Other Expenses	AR$8.45b
Earnings	AR$17.17b

Last Reported Earnings

Sep 30, 2024

Next Earnings Date

n/a

Earnings per share (EPS)	212.60
Gross Margin	68.23%
Net Profit Margin	45.73%
Debt/Equity Ratio	223.8%

How did RICHD perform over the long term?

See historical performance and comparison

Laboratorios RichmondC.I.F BASE:RICHD Stock Report